Patient and disease characteristics at baseline for tested and untested patients by period of diagnosis (period I and period II)
| Characteristics | Period I* | P value | Period II* | P value | ||
| Tested n=137 | Untested n=33 | Tested n=64 | Untested n=15 | |||
| N (%) | N (%) | N (%) | N (%) | |||
| Age at diagnosis, median (IQR) | 66.0 (58.0–72.0) | 70.0 (66.0–75.0) | 0.009 | 66.0 (59.0–72.0) | 65.0 (56.0–78.0) | 0.924 |
| Year of diagnosis | 0.417 | 0.555 | ||||
| 2016 | 36 (26.3) | 12 (36.4) | – | – | ||
| 2017 | 64 (46.7) | 15 (45.5) | – | – | ||
| 2018 | 37 (27.0) | 6 (18.2) | 24 (37.5) | 4 (26.7) | ||
| 2019 | – | – | 40 (62.5) | 11 (73.3) | ||
| BMI at diagnosis, kg/m2 | 0.101 | 0.480 | ||||
| <18.5 | 1 (0.7) | 2 (6.1) | 4 (6.3) | 1 (6.7) | ||
| ≥18.5 and ≤24.9 | 60 (43.8) | 16 (48.5) | 26 (40.6) | 5 (33.3) | ||
| ≥25.0 and ≤29.9 | 41 (29.9) | 12 (36.4) | 24 (37.5) | 4 (26.7) | ||
| ≥30 | 29 (21.2) | 3 (9.1) | 9 (14.1) | 5 (33.3) | ||
| Unknown | 6 (4.4) | – | 1 (1.6) | – | ||
| Country of birth (self-reported) | 0.841 | 1.000 | ||||
| The Netherlands | 107 (78.1) | 26 (78.8) | 47 (73.4) | 12 (80.0) | ||
| Other | 4 (2.9) | – | 2 (3.1) | – | ||
| Unknown | 26 (19.0) | 7 (21.2) | 15 (23.4) | 3 (20.0) | ||
| Educational level† (self-reported) | 0.612 | 0.329 | ||||
| Low | 42 (30.7) | 13 (39.4) | 11 (17.2) | 3 (20.0) | ||
| Medium | 57 (41.6) | 10 (30.3) | 35 (54.7) | 7 (46.7) | ||
| High | 4 (2.9) | 1 (3.0) | – | 1 (6.7) | ||
| Unknown | 34 (24.8) | 9 (27.3) | 18 (28.1) | 4 (26.7) | ||
| Parity at diagnosis (self-reported) | 0.811 | 0.051 | ||||
| Yes | 91 (66.4) | 20 (60.6) | 40 (62.5) | 6 (40.0) | ||
| No | 20 (14.6) | 6 (18.2) | 8 (12.5) | 6 (40.0) | ||
| Unknown | 26 (19.0) | 7 (21.2) | 16 (25.0) | 3 (20.0) | ||
| Smoking status at diagnosis (self-reported) | 0.679 | 0.677 | ||||
| Never smoker | 54 (39.4) | 15 (45.5) | 25 (39.1) | 6 (40.0) | ||
| Former smoker | 46 (33.6) | 11 (33.3) | 24 (37.5) | 4 (26.7) | ||
| Current smoker | 14 (10.2) | 1 (3.0) | 4 (6.3) | 2 (13.3) | ||
| Unknown | 23 (16.8) | 6 (18.2) | 11 (17.2) | 3 (20.0) | ||
| Family history of cancer at diagnosis (self-reported) | 0.864 | 0.406 | ||||
| Yes | 78 (56.9) | 17 (51.5) | 37 (57.8) | 6 (40.0) | ||
| No | 36 (26.3) | 10 (30.3) | 16 (25.0) | 5 (33.3) | ||
| Unknown | 23 (16.8) | 6 (18.2) | 11 (17.2) | 4 (26.7) | ||
| WHO performance status at diagnosis | 0.199 | 1.000 | ||||
| 0 | 77 (56.2) | 20 (60.6) | 36 (56.3) | 9 (60.0) | ||
| 1 | 29 (21.2) | 7 (21.2) | 14 (21.9) | 4 (26.7) | ||
| 2 | 5 (3.6) | 2 (6.1) | 6 (9.4) | 1 (6.7) | ||
| 3 | 1 (0.7) | 2 (6.1) | – | – | ||
| Unknown | 25 (18.3) | 2 (6.1) | 8 (12.5) | 1 (6.7) | ||
| Frailty at diagnosis (GFI) | 0.178 | 0.479 | ||||
| < 4 (non-frail) | 62 (45.3) | 14 (42.4) | 29 (45.3) | 9 (60.0) | ||
| ≥ 4 (frail) | 23 (16.8) | 10 (30.3) | 13 (20.3) | 1 (6.7) | ||
| Unknown | 52 (38.0) | 9 (27.3) | 22 (34.4) | 5 (33.3) | ||
| Histology at diagnosis | 0.019 | 0.006 | ||||
| High-grade serous | 103 (75.2) | 17 (51.5) | 47 (73.4) | 5 (33.3) | ||
| Non-high-grade serous | 31 (22.6) | 14 (42.4) | 17 (26.6) | 10 (66.7) | ||
| Adenocarcinoma NOS | 3 (2.2) | 2 (6.1) | – | – | ||
| FIGO stage at diagnosis | 0.381 | 0.006 | ||||
| I/II | 34 (24.8) | 11 (33.3) | 11 (17.2) | 8 (53.3) | ||
| III/IV | 102 (74.5) | 22 (66.7) | 53 (82.8) | 7 (46.7) | ||
| Unknown | 1 (0.7) | – | – | – | ||
One patient who rejected germline test was not included in analysis by testing status.
*Period I: January 1, 2016, until July 1, 2018. Period II: July 1, 2018, until January 1, 2020.
†Educational levels were defined as follows: low=primary or secondary education or less medium=vocational education; high=university or higher education.
BMI, body mass index; FIGO, International Federation of Gynecology Obstetrics; GFI, Groningen Frailty Index; IQR, Interquartile range; NOS, not otherwise specified.